Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

FORGOTTEN HISTORY: 56 - Caught on Camera

The war on kush: The synthetic drug sweeping through parts of Africa

A new report by an anti-transnational crime group has identified the core chemical components of kush, a synthetic drug that has swept through Sierra Leone and the region in the past few years.

The Independent UK · Feb 25, 2025

The Latest: Musk renews threat to fire federal workers despite pushback from various agencies

Elon Musk is vowing yet again to fire any federal workers who don’t respond to an email asking them to list five things they accomplished last week

The Independent UK · Feb 25, 2025

Biological E Limited partners with Bavarian Nordic to increase global access to Chikungunya Vaccine

This partnership comprises a technology transfer of the current drug product manufacturing process for the Chikungunya Vaccine, with the option to transfer the drug substance process at a later stage. Read further on Dynamite News:

Dynamite News · Feb 25, 2025

From analysis to the latest developments in health,
read the most diverse news in one place.

Why has Unilever CEO Hein Schumacher stepped down and who is replacing him?

Mr Schumacher was named CEO in 2023 following the retirement of Alan Jope but has now stepped down in a surprise move

Evening Standard · Feb 25, 2025

3 Pharmaceutical Stocks With Blockbuster Drug Potential

The pharma industry is delivering game-changing therapies with favorable regulatory support. Amid this backdrop, investors might consider adding three well-positioned biotech stocks such as Vertex Pharmaceuticals (VRTX), BioMarin Pharmaceutical (BMRN), and Gilead Sciences (GILD), for potential gains. Learn more….

StockNews.com · Feb 24, 2025

Gilead Sciences: 4 Reasons This Stock Has Much More To Rise

Gilead Pharmaceuticals is back to highs not seen in a decade as its HIV treatment franchise surges and awaits its 100% effective HIV prevention drug in summer

MarketBeat · Feb 22, 2025

Biogen Stock Is Mutating Into a Value Play

Biogen shares have fallen over 70% from its highs nearly 12-years ago, but value investors should take a look at its metrics of just 12.4 P/E and P/B of 1.2X

MarketBeat · Feb 20, 2025

Read news from The Economist, FT, and more,
with one subscription

Solid Biosciences Soars 32% on Trial Data: 189% Upside from Here?

Solid Biosciences just saw a 32% move to the upside after its trial results impressed. What's next for this firm that analysts still see massive potential in?

MarketBeat · Feb 19, 2025

Moderna: A Generational Opportunity for Investors in 2025

Moderna had a weak quarter but reaffirmed guidance, expecting three new product approvals in 2025 and as many as ten more within three years.

MarketBeat · Feb 19, 2025

These 3 Stocks Just Announced Major Dividend Hikes

See which three stocks just raised their dividend payments by over 15%. On firm now has a sky-high indicated yield of over 10%.

MarketBeat · Feb 18, 2025

Novo Nordisk reprimanded for allegedly failing to disclose payments

The manufacturer of the weight loss jab Wegovy said it ‘is dedicated to working transparently and ethically’.

Evening Standard · Feb 17, 2025

Biotechs on the Brink: 2 Stocks With Huge Potential

BriaCell Therapeutics and Recursion Pharmaceuticals are two biotech firms that may be poised for success in 2025; risk-tolerant investors might keep an eye out.

MarketBeat · Feb 14, 2025

3 Biotech Stocks Revolutionizing Healthcare

Biotech stocks are revolutionizing healthcare with breakthrough innovations, leading the charge in precision therapies and transformative partnerships. To capitalize on this trend, consider adding Amgen (AMGN), BioNTech (BNTX), and Gilead Sciences (GILD), which could boost your portfolio.

StockNews.com · Feb 10, 2025

Merck: 4 No-Brainer Reasons to Buy This Dip

Merck & Co. stock was pummeled by 10% after its earnings release on soft forecasts, but the overreaction by the market may present a buying opportunity.

MarketBeat · Feb 10, 2025

Get all your
news in one place.

100's of premium titles.
One news app.

International Business Times · Feb 10, 2025

Pfizer's Super Bowl 2025 Ad Featuring Young Cancer Survivor Sparks Mixed Reactions

Pfizer's Super Bowl ad received mixed reactions on social media, but many criticized the pharma giant for saying it will "knock out" cancer amid concerns over its COVID-19 vaccine.

Salon · Feb 10, 2025

Is a new painkiller too good to be true?

Meet suzetrigine, a non-opioid that promises to avoid addiction risk. But some experts say it can't replace opioids

The Guardian - UK · Feb 8, 2025

AstraZeneca, Whitehall, and a failed £450m deal for the next generation in vaccines. What went wrong?

When the pharma firm cancelled plans for a major expansion of its Merseyside plant last month, there was no shortage of questions – or blame – over responsibility

International Business Times UK · Feb 7, 2025

Despite Profit Fallout, GSK Remains Optimist For 2031 Revenue Target Amidst Cancer Drug Sale Rise

GSK's oncology sales increased 98% in 2024, and reflects strong demand and potentially new launches or indications for cancer therapies.

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat · Feb 7, 2025

Weak Guidance from Bristol-Myers Could Be Creating an Opportunity

Bristol-Myers stock fell after earnings, but analysts remain bullish which suggests that any dip in the stock may create a buying opportunity

Kiplinger · Feb 6, 2025

Eli Lilly Stock Rises After Profit, Outlook Top Expectations

Eli Lilly stock is higher Thursday after the pharma giant beat fourth-quarter profit expectations and issued strong 2025 guidance. Here's what you need to know.

The Independent UK · Feb 6, 2025

AstraZeneca ‘very disappointed’ after ditching £450m Liverpool vaccine site

Pascal Soriot, chief executive of AstraZeneca, denied any rift with the Government over the decision.

StockNews.com · Feb 6, 2025

Is Harmony Biosciences Holdings Inc. (HRMY) a Biotech Stock to Consider?

Harmony Biosciences’ (HRMY) recently released growth plans and pipeline advancements have showcased the company’s dedication towards being a top contender in the highly contested biotech market. So, should investors looking to capitalize on the industry’s prospects consider investing in HRMY? Read more….

The Guardian - UK · Feb 6, 2025

AstraZeneca ‘very disappointed’ over axed £450m Liverpool vaccine project

As drugmaker reports 38% jump in profits, CEO denies tension with UK government after Speke plant decision

The Guardian - UK · Feb 5, 2025

Drug firm GSK delivers a syringe full of crowd-pleasers

Pharmaceuticals company’s higher dividend, upgrade to revenues and share buyback suggest its drugs pipeline is flowing nicely

MarketBeat · Feb 5, 2025

Earnings Miss? Amgen’s Dividend Still a Bright Spot

AMGN stock is down over 1% despite beating revenue and earnings estimates; investors are selling the news on the company’s latest obesity drug and weak guidance

1 … 55 56 57 58

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.